Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.43 |
| ▸ | ACACA | Q13085 | 4/20 | 0.43 |
| ▸ | PREP | P48147 | 3/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19459507 | 0.82 | PREP (0.38) | ACACBPREP | |
| SCHEMBL19459506 | 0.82 | PREP (0.38) | ACACBPREP | |
| SCHEMBL13721611 | 0.80 | ATM (0.57) | ACACBMEN1KMT2A | |
| SCHEMBL10469262 | 0.80 | PTGS2 (0.46) | PREPNR1H4 | |
| SCHEMBL8379284 | 0.80 | PREP (0.40) | PREPALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL474105 | 0.78 | PREP (0.40) | ACACBPREPALDH1A1MEN1KMT2A | |
| SCHEMBL4909924 | 0.78 | PREP (0.40) | ACACBPREPALDH1A1MEN1KMT2A | |
| SCHEMBL474104 | 0.78 | PREP (0.40) | ACACBPREPALDH1A1MEN1KMT2A | |
| SCHEMBL8382753 | 0.78 | TRPA1 (0.44) | PREPALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10827924 | 0.78 | PREP (0.42) | PREPHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009534-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009534-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | GPR119, LIPC, CEL | ACACB 52/4885ACACA 11/4885PREP 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.